LONDON, Jan 9 (Reuters) - Britain's ReNeuron Group Plc said that trials of its stem-cell therapy for stroke patients had been put on hold by the U.S. Food and Drug Administration (FDA), sending its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback